Results 71 to 80 of about 3,103 (172)
Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model
BACKGROUND: The potential effects of the very effective cystic fibrosis triple combination drug, Elexacaftor/Tezacaftor/Ivacaftor (ETI) in pregnancy on prenatal development of offspring remain largely unknown.Donnelley, M, Habgood, MD, Li, D, Zhu, Y, Schneider-Futschik, EK, Parsons, D +5 morecore +2 more sourcesIntegrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery
Advanced Science, Volume 13, Issue 20, 9 April 2026.Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu +6 morewiley +1 more sourceMejoría de la inflamación intestinal tras tratamiento con moduladores de la proteína CFTR en pacientes con fibrosis quística
Anales de PediatríaResumen: Introducción: Los tratamientos con moduladores de la proteína CFTR han mejorado la salud respiratoria y digestiva de los pacientes con fibrosis quística.Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez +14 moredoaj +1 more sourceThe expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
International audienceBackground Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant.Roy, Charlotte, de Carli, Paola, Richaud-Thiriez, Bénédicte, Montcouquiol, Sylvie, Mayer, Sophie, Audousset, Camille, Mankikian, Julie, Arnouat, Baptiste, Quétant, Sébastien, Audrezet, Marie-Pierre, Verhille, Juliette, Pramil, Stéphanie, Ohlmann, Camille, Campbell, Karine, Hamidfar, Rebecca, Mittaine, Marie, Sermet-Gaudelus, Isabelle, Porzio, Michele, Gachelin, Elsa, Honoré, Isabelle, de Miranda, Sandra, Périsson, Caroline, Socchi, Floriane, Baravalle, Mélisande, Girodon, Emmanuelle, Burnet, Espérie, Llerena, Catherine, Marchal, Sarah, Leroy, Sylvie, Mely, Laurent, Hinzpeter, Alexandre, Blondé, Aurore, Bui, Stéphanie, Coltey, Bérengère, Stremler, Nathalie, Poey, Nora, Grenet, Dominique, Dupuy-Grasset, Magali, da Silva, Jennifer, Gabsi, Asma, Perez, Thierry, Danner-Boucher, Isabelle, Bon, Claire, Chiron, Raphael, Ravoninjatovo, Bruno, Abely, Michel, Foucaud, Pierre, Guillaumot, Anne, Dufeu, Nadine, Kieffer, Sebastien, Nove-Josserand, Raphaële, Belleguic, Chantal, Chedevergne, Frédérique, Fanton, Annlyse, Wizla, Nathalie, Alkoussa, Wael, Cosson, Laure, Durieu, Isabelle, Dalphin, Marie-Laure, Macey, Julie, Murris-Espin, Marlène, Tatopoulos, Aurélie, Perrin, Thomas, Le Rouzic, Olivier, Kanaan, Reem, Duthoit, Louise, Laurans, Muriel, Dehillotte, Clémence, Le Clainche-Viala, Laurence, Nouvel, Thierry, Valois, Sophie, Rames, Cinthia, Thouvenin, Guillaume, Houdouin, Véronique, Reynaud, Quitterie, Corvol, Harriet, Hatton, Aurélie, Deneuville, Eric, Ramel, Sophie, Pranke, Iwona, Priou, Pascaline, Raynal, Caroline, Martin, Clémence, Dupuis, Marion, Burgel, Pierre-Régis, Flament, Thomas, Labbé, Guillaume, Lemonnier, Lydie, Remus, Natascha, Dreano, Elise, Reynaud-Gaubert, Martine, Lebihan, Jean, Marguet, Christophe, Coolen-Allou, Nathalie, Douvry, Benoit, Pouradier, Delphine, Languepin, Jeanne, Scalbert, Manuela, Carlier, Nicolas, Vuillard, Constance, Andrejak, Claire, Weiss, Laurence, Reix, Philippe, Bihouée, Tiphaine +103 morecore +1 more sourceImprovement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients
Anales de Pediatría (English Edition)Introduction: Treatments with CFTR protein modulators have improved respiratory and digestive health in patients with cystic fibrosis. Objective: To assess changes in intestinal inflammation through the analysis of fecal calprotectin in patients with ...Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez, Saioa Vicente Santamaría, Ana Tabares González, Jose Ramon Gutierrez Martinez, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Luis Peña Quintana +20 moredoaj +1 more sourceTherapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis
Background/Objectives: Elexacaftor, tezacaftor, and ivacaftor (ETI) have significantly improved lung function in people with cystic fibrosis (pwCF). Despite exceptional improvements in most cases, treatment-related inter-subject variability and drug ...Melanie Goetschke, Michael Vogeser, Uwe Liebchen, Sarah Sieber, Katharina Habler, Juergen Behr, Christina Shad, Olaf Sommerburg, Magdalena Breuling, Johanna Kastenberger, Susanne Naehrig, Alexandra Katharina Kunzelmann, Michael Paal +12 morecore +1 more source
